Document:

Agreement No.:

 

Health Food Technology Transfer Agreement

 

Project Name:
The transfer of the twelve health food approval numbers of Health Foods, including Dr. Xiao Brand Honeysuckle Pearl Capsule,
Dr. Xiao Brand Multivitamin Tablet, Dr. Xiao Brand Zhengdian
Capsule, Dr. Xiao Brand Shengui Capsule, Dr. Xiao Brand
Multivitamin Tablet (Woman), Dr. Xiao Brand Shikong Soft Capsule, Dr.
Xiao Brand Huangjingdanggui Tablet, Dr. Xiao Brand Xingxing Soft Capsule, Dr.
Xiao Brand Vitamin A Fish Oil Soft Capsule, Dr. Xiao Brand Colon Cleanser Granules,
Dr. Xiao Brand Jianli Soft Capsule and LB Brand Xinpin Capsule, and the trademark ownership of Dr.
Xiao’s No.5 and No.30 category product and LB’s No.30 category product. 

 

Transferee (Party A): Harbin Humankind
Biology Technology Co., Limited

 

Transferor (Party B): Guangzhou Aoda Biology
Beauty Healthy Technology Co., Ltd

 

	Signed
    on           January 18,
    2013                 
	 
	Signed in                     Harbin                         

 

Printed and made by Ministry of Science
and Technology of PRC

 

    	1

    	 

    

 

Instruction

 

I This agreement is a sample printed and
made by Ministry of Science and Technology of PRC. Technology agreement registration administration may recommend this sample to
the parties entering into Technology agreement.

 

II This agreement is applicable to the
agreement where transferor provides knowhow to transferee, specify its usage rights and transfer rights between the parties, and
the usage fees to be paid by transferee.

 

III If there are more than one parties
on one side of agreement, they shall be listed as “common transfee” or “common transferer”, respectively,
under the category of “Principal” and “Agent” (in the added pages), based on their roles in this Agreement.

 

IV For the items not covered in this Agreement,
the parties of the agreement may specify in supplementary pages, which shall be the integral part of this Agreement.

 

V The parties who adopt this sample agreement
shall fill in “none” for those terms that they agreed not to fill in.

 

    	2

    	 

    

 

Health Food Technology Transfer Agreement

 

	Transferee (Party A): Harbin Humankind Biology Technology Co., Limited
	Location: No. 168 Binbei St. Songbei District. Harbin                        
	Legal Representative: Kai Sun                                           
	Contact: Zhiqiang Wang                                                
	Contact Method:                                                      
	Mail address: No. 168 Binbei St. Songbei District Harbin                     
	Tel.:                                     	Fax:                                     
	E-mail:                                                              
	 	 
	Transferor (Party B): Guangzhou Aoda Biology Beauty Healthy Technology Co., Ltd
	Location: 43/F Weiduoli Plaza Tiyuxi Road Tianhe District Guangzhou City       
	Legal Representative: Hui Wu                                           
	Contact: Juan Wu                                                     
	Contact Method:                                                      
	Mail address: 43/F Weiduoli Plaza Tiyuxi Road Tianhe District Guangzhou City   
	Tel.:                                       	Fax:                                     
	E-mail:                                                              

 

Party B will
transfer to Party A the approval numbers and knowhow of twelve health foods, including formula, manufacturing process, quality
standard and product registration approval certificates, as well as the trademarks of Dr. Xiao of No.5 and No.30 category and LB
of No.30 category, and Party A shall pay the consideration to acquire them. The twelve health foods refer to Health Food including
Dr. Xiao Brand Honeysuckle Pearl Capsule(Approval No. Guoshijianzi G20100656), Dr.
Xiao Brand Multivitamin Tablet(Approval No. Guoshijianzi G20080176), Dr. Xiao Brand Zhengdian
Capsule(Approval No. Guoshijianzi G20070261), Dr. Xiao Brand Shengui Capsule(Approval No.
Guoshijianzi G20080297), Dr. Xiao Brand Multivitamin Tablet (Woman) (Approval No. Guoshijianzi
G20070338), Dr. Xiao Brand Shikong Soft Capsule(Approval No. Guoshijianzi G20080096),
Dr. Xiao Brand Huangjingdanggui Tablet(Approval No. Guoshijianzi G20080201), Dr.
Xiao Brand Xingxing Soft Capsule(Approval No. Guoshijianzi G20080080), Dr. Xiao Brand Vitamin
A Fish Oil Soft Capsule(Approval No. Guoshijianzi G20080406), Dr. Xiao Brand Colon Cleanser
Granules(Approval No. Guoshijianzi G20060061), Dr. Xiao Brand Jianli Soft Capsule(Approval
No. Guoshijianzi G20050710), and LB Brand Xinpin Capsule(Approval No. Guoshijianzi G20050770).
Based on friendly discussion and good faith negotiation, contract law of PRC and related
laws, both parties come into the following terms. 

 

    	3

    	 

    

 

Article I The transferred technologysecrets
(knowhow) includes:

 

		1.	Scope of technology secrets: formula, production process and quality criterion etc. 

		2.	Technology index and parameter: refer to transferred technology documents. 

 

Article II In order to guarantee Party
A to apply the technology secrets efficiently, Party B shall provide the following technology documents to Party A:

 

		1.	technology documents used for the government approval;

		2.	original approval certificate and attachments;

		3.	other requirements under Requirements about Health Food Registration Application (Trial) 

 

Article III Time, place and method to deliver
technology documents by Party B

 

		1.	Time: on the time when Party B received full payment from Party A;

		2.	Place: Harbin or by express mail;

		3.	Method: both parties inspect and sign on the transfer record.

 

Article IV Transfer fee and payment method
for transfer approval numbers, technology secrets and trademarks:

 

		1.	Total transfer fees is RMB 30,000,000 including tax fees, trademarks etc.

 

    	4

    	 

    

 

		2.	After the Agreement is effective, Party A shall pay down payment of RMB 4,500,000 to Guangzhou
Aoda Biology Beauty Healthy Technology Co., Ltd. After received the down payment, Party B shall provide technology documents
for production, including formula, manufacturing process, enterprise standard and original trademark certificates etc.

		3.	When Party A completed production of three batches of samples, and filed and confirmed with Heilongjiang
Food and Drug Administration that the transfer may proceed, Party A shall pay the remaining RMB 25,500,000 to Guangzhou Aoda
Biology Beauty Healthy Technology Co., Ltd. Party B shall provide Party A all the technology documents, original approval certificates
and trademarks registration certificates.

 

Article V Party B’s work about executing
or transferring the project technology secrets before the Agreement is effective.

 

Party B’s work about executing the
project technology secrets (time, place, method and scale):

 

The technology secrets were formed
based on small scale trial and middle scale trial during the R&D stage. Party B never enters into the commercialized production
of the technology products.

 

Article VI In order to guarantee Party
A to execute the project knowhow efficiently, Party B shall provide the following technology service and technology guidance.

 

		1.	The content of technology service and guidance. Party B shall direct and assist Party A to complete
qualified products of three batches, and provide consulting and guidance service for registration application of the technology
transfer product.

		2.	The method of technology service and guidance: via phone call or mail, or appoint the staff to
provide on-site guidance service.

 

Article VII Related documents provide by
Party B based on Detailed Requirements on Registration Application of Technology Transfer Products.

 

    	5

    	 

    

 

		1.	Technology documents provided on the transfer of the twelve products 

 

		(i)	Certificates: obtain Health Food Approval Certificates issued by China Food and Drug Administration
(CFDA).

		(ii)	Technology contents, including product R&D report; formula and the basis, usage basis for
raw material and accessory material, the content and inspection method of efficacy ingredient or indicative ingredient, flow chart
of production processing as well as the detailed explanation and related research documents; quality criterion(for company) and
explanation including quality criterion of raw material and accessory material; category, name, quality criterion and basis to
choose of package material with direct contact with product; testing report provided by inspection institution and the related
documents including toxicology security evaluation report, health efficacy evaluation report including animal test and human trail
eating test, efficacy ingredients identification report, stability testing report, and hygienic testing report, product tag, product
description sample, other documents to assist product inspection, and the related work to this project including on-site inspection
on sample testing, selective examination of sample product and check etc. 

		2.	Original Approval Certificate. Obtain Health Food Approval Certificate issued by China Food
and Drug Administration (CFDA).

		3.	Other documents need to be provided by Party B based on the regulation of the sixth article of
Requirements about Health Food Registration Application (trial), Detailed Requirements on Registration Application of Technology
Transfer Products. 

 

Article VIII Other issues related to this
Agreement specified by both parties:

 

		1.	This Agreement is entered into based on Health Food Registration Administration (trial).
Both parties shall conform with the qualifications specified in this regulations. Party B promises to provide the legal documents
and legal procedures for the registration application of the technology transfer product, but will not assume any responsibilities
for the result of the application. Party A shall be responsible for product transfer procedures and pay for the related fees such
as inspection and notary, etc.

 

    	6

    	 

    

 

		2.	Transfer period is not closed until all transfer procedures are completed and commences from the
date which is mutually confirmed by both parties.

		3.	Based on the related regulations in the Administration, Party B promises it did not and will not
manufacture and sell the products. Party B shall transfer the technology documents to Party A when Party A has paid off the consideration.
Party A shall complete the sample production and all preparation work within two months and provide to local Food and Drug Administration
for transfer application. Party B shall fulfill the obligations including provide seal service and related service.

		4.	During the period when this Agreement is executed, Party B is prohibited to transfer the contract
object to the third party. If Party B breaches, it shall compensate RMB 5,000,000 to Party A in addition to refunding the money
Party B has been paid.

		5.	If Party A could not pay for the consideration15 days beyond the deadline of this Agreement, Party
A is considered to waive the transfer. Party B has the rights to terminate the Agreement anytime and pays back to Party A the money
paid to terminate the Agreement.

		6.	If the transfer fails because of Party B, within one week after CFDA declines to approve or within
seven days after Party A inform to terminate the Agreement, or both parties negotiate to fix transfer date and sign supplementary
agreement, Party B shall pay back all money paid by Party A and the Agreement is terminated. If part of products could not be transferred,
Party B shall pay back the money at RMB 2,500,000 each product which is not transferred.

		7.	If the Agreement is not executed because of Party A, Party A has the rights to appoint the third
party as transferee to fulfill the Agreement and Party B shall continue to cooperate to conduct transfer procedures.

 

    	7

    	 

    

 

		8.	If the Agreement could not be executed because of force majeure, both parties will not ask for
compensation for each other include but not limited to the terms and documents which have been performed.

		9.	During the period when the Agreement is executed, if the legal entity of both parties occurs dissolution,
rescind and changes etc., one party shall inform the other party by written notice. Both parties shall specify otherwise or negotiate
to solve the problem about legal entity of rights and obligations.

		10.	During the transfer period, Party B shall permit Party A to manufacture and sell in the name of
Party B and cooperate with Party A. If Party B does not cooperate, it shall compensate RMB 5,000,000 to Party A. In the process
of sell in the name of Party B, if Party A breaches national sales regulation and causes damages to Party B’s fame, Party
A shall compensate the economic loss caused to Party B.

		11.	Because Party B needs the fund urgently, both parties agree to modify the article four of way of
payment based on mutual negotiation. Party A shall pay transfer fees of RMB 30,000,000 at one time to Party B within three business
days after the Agreement is signed and notarized, provided that Party B shall provide contract guarantee of ownership of all Baidaifu
trademarks and manufacture qualification under the name of Guangzhou Aoda Biology Beauty Healthy Technology Co., Ltd. The contact
guarantee shall be released if Party A completes sample production of three batches and make the application to Heilongjiang Food
and Drug Administration which confirms the transfer could be accepted.

		12.	If Party A has paid off the consideration, but Party B could not cooperate with Party A to complete
the transfer, Party B shall double compensate Party A. including all related fees occurred during transfer period. In order to
guarantee the economic benefit of both parties, Party B shall provide all transfer documents within seven days after the Agreement
is signed. Within two business days after inspection and confirmation by authorized person from Party A, Party A will shall transfer
the money to the bank account of Party B. Concurrent with wire payment, Party B shall provide all documents to Party A.

		13.	Dr. Xiao Brand Colon Cleanser Granules, Dr.
Xiao Brand Jianli Soft Capsule, and LB Brand Xinpin Capsule are at re-registration stage and
are not possible for transfer at the stage. The three products also involve in new standard approval regarding to future re-registration
of health foods. Because the transfer involves potential risk, both parties come into the following terms after friendly negotiation:

 

    	8

    	 

    

 

(i) Party
B shall assume the related feesfor registration of Dr. Xiao Brand Colon Cleanser Granules, Dr.
Xiao Brand Jianli Soft Capsule, and LB Brand Xinpin Capsule. , Failure to do so will be deemed
as breach of contract. 

(ii) With
respect to all documents related to re-registration, Party B shall provide and submit them to Authorities for approval on time
to guarantee the approval of Dr. Xiao Brand Colon Cleanser Granules, Dr. Xiao Brand Jianli
Soft Capsule, and LB Brand Xinpin Capsule. Failure to do that will be deemed as default and
Party B shall assume the liablities.

(iii) Dr.
Xiao Brand Colon Cleanser Granules, Dr. Xiao Brand Jianli Soft Capsule, and
LB Brand Xinpin Capsule is not available for transfer at this stage. After complete the re-registration of the three products,
Party B shall transfer to Party A Dr. Xiao Brand Colon Cleanser Granules, Dr. Xiao Brand
Jianli Soft Capsule, and LB Brand Xinpin Capsule in time.

(iv) If Party
B makes efforts to cooperate the re-registration of Dr. Xiao Brand Colon Cleanser Granules, Dr.
Xiao Brand Jianli Soft Capsule, and LB Brand Xinpin Capsule, yet fails to transfer the three
technologies to Party A, Party B shall pay back the transfer fees at RMB 2,500,000 for each product within seven business days.

 

Article IX The Agreement is exclusive.
If Party B breaches, it shall pay RMB 1,000,000 to Party A as breaching compensation.

 

Article X For any disputes arise from executing
this Agreement, both parties shall negotiate to settle the disputes. If the disputes are not settled by negotiation, either party
may bring the lawsuit in the court where the plantiff resides.

 

    	9

    	 

    

 

Article XI As for the items not covered
in this Agreement, both parties need to sign supplementary agreement which has the same legal effect with this Agreement.

 

Article XII This Agreement is executed
in six copies. Party A and Party B held three copies respectively.

 

This Agreement is taken into effect after
the authorized representatives of both parties sign, seal and notarize the Agreement.

 

Party A: Harbin Humankind Biology Technology
Co., Limited

Authorized representative: /s/Zhiqiang
Wang

Signed on January 18, 2013

 

Party B: Guangzhou Aoda Biology Beauty
Healthy Technology Co., Ltd

Authorized representative: /s/Juan Wu

Signed on January 18, 2013

 

    	10Stock Transfer Agreement

 

Transferor: Wenbin Zhang (hereinafter referred
as Party A)

 

Identity document: ID card ID No. 222401197110080033

 

Transferee: Harbin Humankind Biology Technology
Co., Limited (hereinafter referred as Party B)

 

(Seal)

 

Whereas Party A legally owns 31.5% of equity
stock of Heilongjiang Huimeijia Pharmaceuticals Co., Ltd (hereinafter referred as “the Company”) and has decided to
transfer all 31.5% of equity stock, and that the shareholders meetings of the Company have approved the transfer.

 

Whereas Party B agrees to acquire the 31.5%
of equity stock of Company held by Party A.

 

Whereas shareholder of Company agree Party
B to acquire the 31.5% of equity stock of Company held by Party A.

 

Based on the principles of friendly negotiation,
mutual benefit and consensus, both parties enter into the following agreements on the equity stock transfer:

 

Article I The quantity and price of
transferred equity stock

 

	1.	Party A agrees to transfer to Party B 31.5% of equity stock of Company held by himself. Party B
agrees to acquire the said equity stock.
	 	 
	2.	The equity stock to be transferred includes its attached interest and rights and is not subject
to (including but not limited to) any lien, mortgage and other interests or rights from the third party.
	 	 
	3.	Party A will be not responsible for any debt, obligation , liabilities or management responsibilities
of the Company,, after the Agreement comes into effect.
	 	 
	4.	Based on the terms of this Agreement, Party A transfers the 31.5% equity stock of Company for the
consideration of RMB 31,500,000. Party B agrees to acquire the equity stock for the consideration.

 

    	1

    	 

    

 

Article II Term and Method to transfer
the stock

 

Party B agrees to pay the price by the
following term and method:

 

Party B agrees to wire the payment to the
bank account designated by Party A by installment within three months after both parties signed the Agreement. Meanwhile, both
parties need to start the changes of business registration etc.

 

Article III Shareholder’s
rights and obligations

 

	1.	From the effected date of this Agreement on, Party B will execute the shareholder’s rights
and fulfill the shareholder’s obligations. If necessary, Party A shall assist Party B to execute shareholder’s rights
and fulfill shareholder’s obligations, including sign related documents in the name of Party A.
	 	 
	2.	From the effected date of this Agreement on, Party B shall share the profit and assume risk and
loss based on its percentage of total equity stock.

 

Article IVLiabilities of Breach

 

	1.	If one party is default or breaches any terms of this Agreement, the breaching party shall compensate
the other party for all its economic loss. Unless otherwise specified, the obeying party also has the right to request terminating
the Agreement andclaim any damage from the breaching party
	 	 
	2.	If party B would not pay the consideration within the timeline specified in the Article II of this
Agreement, it shall pay the penalty of 1 ‰ of delayed payment for each delayed day. After the
payment of penalty, if the breaching causes more loss than penalty, or causes other damages, Party A still has the rights to ask
for more compensation for the part which the loss is over the penalty or for the part of other damages.

 

Article V Dispute resolution

 

    	2

    	 

    

 

As for all disputes arise from executing
this Agreement or related to this Agreement, both parties need to settle the disputes by friendly negotiation. If the disputes
are not settled by negotiation, any party has the rights to settle by the following methods:

 

	1.	Submit the dispute for arbitration. The arbitration committee will arbitrate the disputes based
on current arbitration. The arbitration decision shall be final and binding on both parties.
	 	 
	2.	Bring a lawsuit in the local court respectively.

 

Article VI Effect and Termination
of Agreement

 

Effect Terms:

 

	1.	This Agreement is taken in to effect after both parties sign and seal.
	 	 
	2.	After the Agreement is in effect, if any party intends to modify the Agreement, it shall inform
to the other party in written form 10 days in advance. The supplementary agreement could be signed based on written negotiated
agreement. The supplementary agreement is with the same legal effect with the Agreement.

 

Termination Terms:

 

This Agreement could be modified or terminated
if either one of the following occurred.

 

	1.	This Agreement could not be executed for the force majeure or any causes that one party could not
avoid even if it has no faults.
	 	 
	2.	Either party loses the ability to fulfill this Agreement.

 

This Agreement is executed in four copies,
held by Party A, Party B, Company and Industry and Business Authority. All four copies are with the same legal effect.

 

Transferor: /s/Wenbin Zhang

Transferee: Harbin Humankind Biology Technology
Co., Limited (Seal)

 

Signed on April 10, 2013

 

    	3

    	 

    

 

Supplementary Agreement of Stock Transfer
Agreement

 

Transferor: Wenbin Zhang (hereinafter refers
to Party A)

 

ID card No. 222401197110080033

 

Transferee: Harbin Humankind Biology Technology
Co., Limited (hereinafter refers to Party B)

(Seal)

 

The terms used in this Agreement, unless
otherwise specified, contain the same meaning as the definitions in Stock Transfer Agreement (hereinafter refers to Original Agreement)
signed on April 10, 2013.

 

Whereas:

 

Both parties entered into that certain
Stock Transfer Agreement on April 10, 2013 about Harbin Humankind Biology Technology Co., Limited to acquire the 31.5% equity stock
of Heilongjiang Huimeijia Pharmaceuticals Co., Ltd (hereinafter refers to HLJ Huimeijia) held by Party A.

 

Based on the principle of mutual benefit
and friendly negotiation, both parties agree to modify the terms of Original Agreement and enter into the following supplementary
agreement:

 

Article I The amendment to the Original
Agreement

 

Article III Shareholder’s rights
and obligations of Stock Transfer Agreement is modified and amended into the following terms:

 

(i) Both parties agree that Party B shall
wire 10% of price of transferred shares to an independent third party for escrow. Within seven business days upon the completion
of the changes in registration of industry and commerce administration of HLJ Huimeijia, the independent third party will wire
the money to the bank account appointed by Party A.

 

    	4

    	 

    

 

(ii) From the effective date of this Agreement,
Party B shall begin to assume the procedural rights and obligations of shareholder. However, Party B can not assume substantial
rights and obligations, such as ownership on land use rights and the rights to vote on key issues, until the changes in registration
of industry and commerce administration of HLJ Huimeijia are completed and Party A has obtained the remaining consideration set
forth in the Original Agreement.

 

Article II From the effective date
of this Agreement, it will constitute an integral part of Original Agreement and has the same legal effect as the Original Agreement.
If there is any inconsistency between this Agreement and the Original Agreement, this Agreement prevails.

 

Other than the modified terms in this Agreement,
other terms in Original Agreement remain to be effective.

 

Article III This Agreement is taken
into effect after both parties execution and seal.

 

Article IV This Agreement is executed
in four copies, held by Party A, Party B, HLJ Huimeijia and Industry and Business Authority. All four copies are with the same
legal effect.

 

Transferor: /s/ Wenbin Zhang

Signed on June 18, 2013

 

Transferee: Harbin Humankind Biology Technology
Co., Limited (Seal)

Signed on June 18, 2013

 

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]